A Study Describing the Efficacy and Safety of Belimumab Administered in Adult Participants With Early Systemic Lupus Erythematosus (SLE)

To join this study, you would need to have been diagnosed with lupus within the last two years. You'd also need certain positive results from blood tests (like ANA and dsDNA antibodies) that show your immune system is overactive, which is typical in lupus. Your lupus symptoms would still need to be active, meaning your current regular treatment hasn't completely settled things down. Doctors use a special scoring system to check this. Crucially, at the start of the study, you shouldn't have any permanent organ damage from lupus yet.

There are also some reasons why you might not be able to join. For example, if you've had certain types of cancer in the last five years (excluding some skin cancers that have been fully treated). You also wouldn't be able to join if you have other serious uncontrolled health problems not related to your lupus, or if you've had a major organ transplant. The study is open to both men and women aged 18 and over. Women who could become pregnant would need to use effective contraception.

If you decide to take part in this study, you would receive the study medication, Belimumab. This is a special type of drug designed to help calm an overactive immune system in lupus. You would have regular visits to the clinic over a period of three years. These visits would involve assessments like physical examinations, blood tests, and questionnaires to track your lupus symptoms and how you're feeling. The medical team would carefully monitor your health and any side effects throughout the study. While the exact schedule isn't detailed here, clinical studies typically involve frequent visits at the beginning, becoming less frequent over time. You would continue to receive care from the study team for the full duration of the three years.